Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crestor Advisory Meeting Weighs Value Of C-Reactive Protein Risk Marker

Executive Summary

In deciding whether to approve AstraZeneca's Crestor (rosuvastatin) for wider use, FDA will need to say what role high sensitive C-reactive protein levels will play in determining who should take the statin as a preventive measure. Until then, the size of Crestor's market opportunity for the pending claim remains somewhat unclear

You may also be interested in...



Crestor Label Lends Validity To Controversial C-Reactive Protein Test

FDA has cleared AstraZeneca's statin Crestor for wider use in preventing heart disease and related cardiovascular events, in the process validating the controversial high sensitivity C-reactive protein test as a risk marker, some experts say

Crestor Label Lends Validity To Controversial C-Reactive Protein Test

FDA has cleared AstraZeneca's statin Crestor for wider use in preventing heart disease and related cardiovascular events, in the process validating the controversial high sensitivity C-reactive protein test as a risk marker, some experts say

Crestor Label Lends Validity To Controversial C-Reactive Protein Test

Some cardiologists dispute aspects of new label for primary prevention of heart disease.

Related Content

Topics

UsernamePublicRestriction

Register

PS051777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel